[go: up one dir, main page]

WO1996013267A3 - Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome - Google Patents

Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome Download PDF

Info

Publication number
WO1996013267A3
WO1996013267A3 PCT/US1995/013624 US9513624W WO9613267A3 WO 1996013267 A3 WO1996013267 A3 WO 1996013267A3 US 9513624 W US9513624 W US 9513624W WO 9613267 A3 WO9613267 A3 WO 9613267A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
brimonidine
glaucoma
derivatives
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/013624
Other languages
English (en)
Other versions
WO1996013267A2 (fr
Inventor
Michael E Garst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO1996013267A2 publication Critical patent/WO1996013267A2/fr
Publication of WO1996013267A3 publication Critical patent/WO1996013267A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des combinaisons d'agents adrénergiques alpha tels que la brimonidine et ses dérivés tels que représentés par la formule (I), dans laquelle chaque Y est choisi séparément dans le groupe consistant en N, N-CH3, O, S et C-R1; R1 représente hydrogène, oxo ou alkyle inférieur; R2, R3 et R4 sont choisis séparément dans le groupe consistant en hydrogène, halogène, alkyle inférieur et alcényle inférieur; n vaut un entier de 1 à 3; et une ligne en pointillés à côté d'une ligne pleine indique soit une liaison simple soit une liaison double, à condition que lorsque n=1, les deux liaisons entre Y et C-R1 ne puissent être des liaisons doubles, et des prostaglandines connues en soi utilisées pour induire une baisse de la pression intraoculaire. Ces combinaisons sont utiles dans des compositions, des méthodes de traitement et des articles produits, destinés au traitement du glaucome et à l'atténuation d'une pression intraoculaire élevée.
PCT/US1995/013624 1994-10-27 1995-10-20 Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome Ceased WO1996013267A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33005094A 1994-10-27 1994-10-27
US08/330,050 1994-10-27

Publications (2)

Publication Number Publication Date
WO1996013267A2 WO1996013267A2 (fr) 1996-05-09
WO1996013267A3 true WO1996013267A3 (fr) 1996-07-04

Family

ID=23288106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013624 Ceased WO1996013267A2 (fr) 1994-10-27 1995-10-20 Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome

Country Status (1)

Country Link
WO (1) WO1996013267A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856329A (en) * 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6353014B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
EP0968183A2 (fr) 1997-03-07 2000-01-05 Alcon Laboratories, Inc. 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
EP2329849B1 (fr) 2009-11-18 2015-04-29 Galderma Research & Development Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
HUE033143T2 (en) 2010-03-26 2017-11-28 Galderma Res & Dev Preparations containing brimonidine for the treatment of erythema
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
EP2444068B2 (fr) 2010-10-21 2017-12-06 Galderma S.A. Composition de gel de brimonidine
JP2014520895A (ja) * 2011-07-20 2014-08-25 アラーガン インコーポレイテッド ビマトプロストおよびブリモニジンの固定用量の組み合わせ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (fr) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008585A1 (fr) * 1992-10-13 1994-04-28 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SERLE JB: "Pharmacological advances in the treatment of glaucoma.", DRUGS AGING, SEP 1994, 5 (3) P156-70, NEW ZEALAND *

Also Published As

Publication number Publication date
WO1996013267A2 (fr) 1996-05-09

Similar Documents

Publication Publication Date Title
WO1996013267A3 (fr) Combinaisons de prostaglandines et de brimonidine ou de leurs derives pour le traitement du glaucome
EP1225168A3 (fr) Dérivés de prostaglandines pour le traitement du glaucome et de l'hypertension oculaire
TR200003844T2 (tr) Epotilon türevleri, sentezleri ve kullanımları
MY121967A (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
GEP20115347B (en) Heterocyclocarboxamide derivatives
IL157773A0 (en) 2-amino-propanol derivatives
BG103485A (en) Ketobanzamides as calpain inhibitors
MXPA03004165A (es) Mezclas de caucho que contienen gel con peroxidos inorganicos.
AU3192195A (en) Thiazolidinedione derivatives, their production and use
WO1996013259A3 (fr) Procede et combinaisons servant a inhiber les proteine kinases
CA2221110A1 (fr) Utilisation de derives d'acide cyclopentane heptan(ene)oique, 2-heteroarylalkenyle en tant qu'agents therapeutiques pour le traitement de l'hypertension oculaire
EP0437030A3 (en) Use of 4-substituted imidazoles for lowering intraocular pressure
HK1049479A1 (zh) 降眼壓類脂類
NZ506497A (en) Indole derivatives, pharmaceuticals thereof and their use in lowering intraocular pressure or for the treatment or prevention of glaucoma or ocular hypertension
ATE160792T1 (de) Oligomere, sterisch gehinderte polyamin-vernetzer und diese vernetzer enthaltende überzugsmasse
MY132550A (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
WO1999002532A3 (fr) Composes polycycliques partiellement hydrogenes
AU6597790A (en) Use of 6- or 7-hydroxyindole derivatives as couplers and dyeing compositions and methods using these
MY100512A (en) New 6-or 7-methlenandrosta-1, 4-diene-3, 17-dione derivatives and process for their preparation.
WO2004019874A3 (fr) Composes de 5-chroman-5-yl-ethylamine substitues et leur utilisation dans le traitement du glaucome
WO2004054572A3 (fr) Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
EP1121932A4 (fr) Medicaments pour maladies oculaires
MY111216A (en) 2-hydroxy-3-[1-(1h-imidazol-4-yl)alkyl]-benzenecarboximidamides
WO2001044327A3 (fr) Procede de preparation d'un produit de reaction polymere
EP0355689A3 (fr) Dérivés de pyrano [f] quinoline et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase